Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Debt (2016 - 2020)

Amicus Therapeutics' Non-Current Debt history spans 10 years, with the latest figure at $147.8 million for Q2 2020.

  • For the quarter ending Q2 2020, Non-Current Debt rose 0.57% year-over-year to $147.8 million, compared with a TTM value of $147.8 million through Jun 2020, up 0.57%, and an annual FY2019 reading of $147.4 million, changed 0.44% over the prior year.
  • Non-Current Debt for Q2 2020 was $147.8 million at Amicus Therapeutics, roughly flat from $147.6 million in the prior quarter.
  • The five-year high for Non-Current Debt was $147.8 million in Q2 2020, with the low at $21.9 million in Q2 2016.
  • Average Non-Current Debt over 4 years is $114.5 million, with a median of $146.8 million recorded in 2019.
  • Year-over-year, Non-Current Debt skyrocketed 318.21% in 2016 and then increased 0.37% in 2019.
  • Tracing FOLD's Non-Current Debt over 4 years: stood at $22.0 million in 2016, then soared by 567.67% to $146.7 million in 2018, then increased by 0.44% to $147.4 million in 2019, then rose by 0.31% to $147.8 million in 2020.
  • Per Business Quant, the three most recent readings for FOLD's Non-Current Debt are $147.8 million (Q2 2020), $147.6 million (Q1 2020), and $147.4 million (Q4 2019).